“Kevin’s impressive credentials in the clinical service, molecular diagnostics, and pre-clinical and clinical pharma, should serve us well as we continue to develop Enzo Clinical Labs into a molecular and esoteric center of excellence,” said Barry Weiner, President of Enzo Biochem, Inc. “Kevin’s extensive operational experience along with his success in the launching of new service offerings will be instrumental in growing Enzo Clinical Labs.”
Prior to joining Enzo Clinical Labs, Dr. Krenitsky, who is replacing Shahram Rabbani, was Chief Executive Officer of Bioserve Biotechnologies Ltd, a global biotech company that validates, processes, and develops molecular diagnostics. Prior to Bioserve, he was Chief Executive Officer of Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing. He previously served as Senior Vice President and Division Head at SeraCare Life Sciences’ Genomics Collaborative Division (GCI), where he managed all worldwide diagnostic and pharmaceutical R&D collaborations. Before GCI was acquired by Seracare Life Sciences, Dr. Krenitsky acted as the company’s Medical Director, responsible for spearheading the development of GCI’s global network of five hundred-plus clinical sites on four continents. During his tenure at GCI, Dr. Krenitsky was instrumental in developing several hundred agreements with dozens of major pharmaceutical, biotechnology, and diagnostic companies worldwide.
Dr Krenitsky received his M.D. from Jefferson Medical College.
About Enzo
Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo’s Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 33,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's Disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo’s Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company’s technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 230 patents worldwide, and has pending applications for over 200 more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
# # #
Contact:
For: Enzo Biochem, Inc.
Steven Anreder, 212-532-3232 Or Michael Wachs, CEOcast, Inc., 212-732-4300